Bayer adds menopause drug to pipeline with KaNDy acquisition

Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline.

Astellas pushes non-hormonal menopause drug into phase 3

UK's KaNDy Therapeutics funds mid-stage trial of HRT 'replac...

Biotech hopes for IPO or big pharma deal to fund phase 3